Updates on HER2-Directed ADCs Across Solid Tumors

Vijayakrishna Gadi, MD, PhD, sets the stage for a discussion around HER2-directed ADCs in the solid tumor space.

EP. 1: Assessing HER2 Status Across Tumor Types

June 25th 2024

Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.

EP. 2: ADCs Targeting HER2+ Breast Cancer

June 25th 2024

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

EP. 3: ADCs Targeting HER2+ Gynecologic Cancers

July 12th 2024

Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.

EP. 4: Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

July 12th 2024

Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.

EP. 5: ADCs Targeting GI Cancers

July 12th 2024

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

EP. 6: ADCs Targeting HER2+ Lung Cancer

July 12th 2024

Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.

EP. 7: Impact of ADCs on Brain Metastases

July 23rd 2024

A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.

EP. 8: ADCs Targeting HER2+ GU Cancers

July 23rd 2024

A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers

EP. 9: Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

August 1st 2024

A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.

EP. 10: The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

August 1st 2024

Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.

EP. 11: Managing ILD and Pneumonitis Risk From ADCs

August 8th 2024

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

EP. 12: Managing Toxicities in Short- and Long-Term Treatment with ADCs

August 8th 2024

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

EP. 13: Managing Hematologic AEs Associated with ADC Treatments

August 15th 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

EP. 14: Management of Emetogenicity of Antibody-Drug Conjugates

August 15th 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

EP. 15: ADC Sequencing

August 22nd 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

EP. 16: Emerging ADCs in Development

August 22nd 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

EP. 17: Insights on T-DXd Approval as Tumor-Agnostic HER2-Directed Therapy

August 29th 2024

Ronan Kelly, MD, MBA, offers insights on trastuzumab deruxtecan approval as tumor-agnostic HER2-directed therapy.

EP. 18: The Future for HER2-Directed ADCs

August 29th 2024

Ronan Kelly, MD, MBA, offers insights on the future for HER2-directed antibody-drug conjugates.

EP. 19: Key Takeaways and Closing Thoughts on ADCs

August 29th 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.